Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Inovio Pharmaceuticals

Moderna

America's highest-profile medical professional waxes optimistic on the potential for a "safe and effective" vaccine by 2021.

Coronavirus Vaccine Developers Rise After Fauci's Comments

Amazon

Penn Entertainment

Nio, Penn National Gaming, Amazon and Novavax were our top stock trades for Monday. That said, let's take a look at the charts.

4 Top Stock Trades for Monday: AMZN, PENN, NIO, NVAX

Netflix

Major market benchmarks oscillated around the unchanged mark.

Stock Market Stays Flat Friday as Netflix Earnings Signal Future Slowdown; Novavax Keeps Soaring on Vaccine Hopes

Vaxart

These three vaccine stocks show no signs of slowing down their breathtaking pace of growth.

3 Game-Changing Coronavirus Vaccine Stocks That May Make You Rich

Quest Diagnostics

Labcorp Holdings Inc

Pfizer

Regeneron Pharmaceuticals

Sanofi

COVID-19 crushed the stock market in March. The only real survivors were companies involved with testing, treatments and vaccines.

8 Coronavirus Stocks That Can Deliver Even More Upside Ahead

Novavax just received the Trump administration’s largest vaccine contract. In the Maryland company’s 33-year history, it has never brought a vaccine to market.

How Novavax Won $1.6 Billion From Operation Warp Speed For Coronavirus Vaccine

Altimmune

Dynavax Technologies

NantKwest

VBI Vaccines

My COVID-19 Vaccine Report Card

Investors are eyeing clinical results later this month and later this year before committing to buying more NVAX stock.
The post Novavax Stock Has Probably Topped Out Until Successful Clinical Trials appeared first on InvestorPlace.

Novavax Stock Has Probably Topped Out Until Successful Clinical Trials

There's no time like the present with this high-flying biotech stock.

3 Reasons to Buy Novavax Stock Sooner Rather Than Later

Can one of the year's top-performing biotech stocks keep climbing?

Is Novavax Still a Good Coronavirus Stock to Buy?

BioNTech SE

Johnson & Johnson

Two experimental coronavirus vaccines, manufactured jointly by Pfizer and BioNTech, have received fast track status from the FDA.

Race to Coronavirus Vaccine Heats Up: 5 Stocks in Spotlight

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?

Is  (NVAX) Outperforming Other Medical Stocks This Year?

Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?

As of late, it has definitely been a great time to be an investor in Novavax, Inc. (NVAX).

Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?

Anthem

Etsy

Southwest Gas Hlds

T-Mobile US

It will be prudent to invest in companies from the tech, healthcare and utility sectors, which are expected to have suffered less compared to others in Q2.

Coronavirus to Cast a Pall Over Q2 Earnings: 5 Stocks to Stand Out

There are good reasons to consider this small biotech an emerging favorite in the COVID-19 vaccine race.

3 Green Flags for Novavax's Future

The U.S. government has awarded biotech company Novavax $1.6 billion towards trials, commercialization, and manufacturing of its potential Covid-19 vaccine candidate NVX-CoV2373. [1] This marks the largest award yet under “Operation Warp Speed” a federal government program that intends to.

Is Novavax A Better Investment Than Moderna?

After its impressive run since the year started, the vaccine maker's stock still has upside potential.

Is It Too Late to Buy Novavax’s Stock?

This analyst thinks Novavax’s stock has little upside left.

Why Novavax Stock Slumped Today

With late-stage clinical development costs covered by the government's funds, Novavax is cleared for takeoff.

Novavax's Vaccine Just Scored $1.6 Billion From Operation Warp Speed. Here's What It Means for Investors.

Novovax (NVAX) is evaluating a coronavirus vaccine candidate, NVX-CoV2373, in a phase I/II study. A pivotal study is due to start in the fourth quarter.

Novovax Up on $1.6B Federal Funding for Coronavirus Program

AstraZeneca

Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp speed.”

Is There a Coronavirus Vaccine Yet?

Walmart

AbbVie

Livongo Health Inc

AbbVie, Livongo, Walmart and Novavax were our top stock trades for Wednesday. That said, let's look at the charts to see what's going on.

4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX

Virtus LifeSci Biotech Clinical Trials ETF

Amplify Treatments Testing & Advancements ETF

Exchange-traded funds with exposure to biotech stocks rocketed higher Tuesday on hopeful news about treatments for COVID-19.

Novavax's 30% surge boosts biotech ETFs to best day in weeks

Major benchmarks were mixed to start the day.

News for Novavax Stock (NVAX)